Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche buys 'disruptive' nanopore genome sequencing tech firm Genia

This article was originally published in Clinica

Executive Summary

Roche may have been thwarted when it tried to acquire genome sequencing leader Illumina, but is now betting on a promising earlier-stage technology with the acquisition of Genia Technologies. The deal, worth $125m upfront in cash, plus milestones of up to $225m, gives Roche a gateway into the emerging nanopore sequencing segment – the method is expected to “reduce the price of sequencing while increasing speed and sensitivity.”





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts